Dendreon (DNDNQ) Stock Price, News & Analysis

Company Overview

Dendreon Corporation was a biotechnology company focused on developing and commercializing innovative cancer treatments. The company’s best-known product was Provenge (sipuleucel-T), an autologous cellular immunotherapy designed to stimulate a patient’s immune system to target prostate cancer.

Provenge received approval from the U.S. Food and Drug Administration in 2010 for the treatment of certain men with metastatic castration-resistant prostate cancer. The therapy was manufactured using a patient’s own immune cells, which were collected, treated outside the body, and reinfused as part of a personalized treatment process.

Headquartered in Seattle, Washington, Dendreon served the U.S. oncology market through its commercial and manufacturing operations. The company filed for Chapter 11 bankruptcy protection in 2014, after which its assets and Provenge-related operations were sold to other companies. Dendreon Corporation is no longer an independent operating public company, and its former shares trade on the over-the-counter market under the symbol DNDNQ.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:DNDNQ
• Previous Symbol: NASDAQ:DNDN
• CIK: N/A
• Web: www.dendreon.com
• Phone: +1-206-2197815
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A